Newly Identified DNA Switch Acts as Molecular Brake on Common Breast Cancer Growth

Adelaide University researchers have identified a hidden DNA switch that acts as a molecular brake on the most common form of breast cancer. The discovery explains how the body naturally suppresses tumor growth in estrogen receptor-positive (ER+) disease, offering a new target for advanced therapies.[2][4]

The findings, published on August 25, 2026, in the journal npj Breast Cancer, resolve a long-standing biological mystery. Scientists have known that activating the androgen receptor can halt tumor progression, but the exact molecular machinery driving this cellular defense remained unclear until now.[2][3]

Up to 80 percent of all breast cancer cases are classified as ER+, meaning their growth is stimulated by the hormone estrogen. Standard endocrine therapies are typically administered for 5 to 10 years to block estrogen production or activity, forming the backbone of current treatment protocols.[4]

Breast cancer remains the most commonly diagnosed cancer globally, with over 2.3 million new cases reported annually by the World Health Organization. Because the vast majority of these are ER+, even a small improvement in targeted therapy could translate to hundreds of thousands of extended lives.[2]

However, resistance to these frontline therapies eventually develops in roughly 20 to 30 percent of patients with advanced disease. When tumors stop responding to traditional estrogen-blocking drugs, finding effective, targeted alternatives becomes a critical race against time for oncologists.[2]

As a result, researchers have increasingly looked to the androgen receptor—a second hormone receptor present in these malignant cells—as an alternative therapeutic target. Activating this receptor has shown significant promise in experimental models, prompting ongoing Phase 1 and Phase 2 clinical investigations worldwide.[2][4]

Developing effective treatments requires a precise understanding of how the receptor operates at the genetic level. Without knowing the exact mechanism, clinicians struggle to predict which patients will benefit most from emerging androgen-targeted therapies, making this new discovery a crucial stepping stone.[2]

The ZBTB16 Mystery

The international research team, spanning 3 institutions across 2 continents, initially focused on a single gene called ZBTB16. Previous data indicated that higher levels of this gene correlated with improved survival outcomes in ER+ breast cancer patients.[2][4]

The working hypothesis was that ZBTB16 directly contributed to the tumor-suppressing process. To test this, the investigators manipulated the gene's expression levels in breast cancer cells, expecting to see a corresponding change in tumor growth rates.[2]

The laboratory results defied initial expectations. Directly altering ZBTB16 levels did not change the androgen receptor's ability to suppress cell proliferation in the experimental models. The gene itself was not the active brake pedal the researchers were looking for, forcing the team to look closer.[2]

"The surprising finding was that ZBTB16 itself was not responsible for the growth-suppressing effect," said Dr. Amy Dwyer from Adelaide University's School of Medicine. The true mechanism was hidden deeper within the genetic code, operating independently of the gene's primary function.[2][3]

Uncovering the HRRINT3 Switch

Instead of the gene itself, the researchers identified a small regulatory region of DNA embedded within ZBTB16. This hidden sequence, designated HRRINT3, functions as an enhancer—a specialized section of DNA that controls the activity and expression of other genes.[2][4]

AI

"Instead, we found that a small DNA 'switch' sitting inside the gene helps the androgen receptor to restrain cancer cell growth," Dwyer explained. This enhancer proved to be the critical component in the tumor-suppression pathway that had previously eluded scientists.[2][3]

When activated by androgens—hormones naturally present in both women and men—the androgen receptor binds directly to the HRRINT3 enhancer. This specific binding event triggers a cascade of genetic instructions that ultimately halts the division of malignant cells.[2][4]

To confirm the enhancer's role, the team utilized CRISPR-Cas9 gene-editing technology. They precisely deleted a small section of the HRRINT3 sequence in laboratory cell models to observe the biological consequences of its absence on tumor development.[2][4]

CRISPR-Cas9 acts as molecular scissors, allowing scientists to make precise cuts in the DNA sequence. By targeting the HRRINT3 enhancer specifically, the team could isolate its function without disrupting the surrounding genetic architecture of the ZBTB16 gene.[4]

The CRISPR Deletion Results

The impact of removing the DNA switch was immediate and profound across the experimental models. Without the intact HRRINT3 enhancer, the androgen receptor lost its ability to effectively control the malignant cells, allowing the breast cancer to multiply unchecked.[2][4]

"When we deleted this DNA 'switch', the androgen receptor could no longer suppress breast cancer cell growth as effectively," said co-author Dr. Zeyad Nassar, a cancer researcher with SAiGENCI and the South Australian Health and Medical Research Institute (SAHMRI).[2][3]

Following the CRISPR deletion, the researchers observed a broader disruption of androgen receptor signaling across the edited cells. Simultaneously, they recorded a marked increase in activity among the specific genes responsible for driving rapid cell division and tumor expansion.[2][4]

"This tells us that the enhancer is doing much more than simply controlling ZBTB16," Nassar noted. "It appears to be part of a wider regulatory network that helps the androgen receptor keep cancer cell proliferation in check."[2][3]

Broader Implications for Oncology

The function of the HRRINT3 switch does not appear to be limited to ER+ breast cancer. The research team expanded their investigation to test the enhancer's role in 2 distinct hormone-driven malignancies, yielding similarly striking results in both.[2][4]

Removing the DNA switch caused rapid cell growth in other androgen receptor-positive breast and prostate cancer cell models. This suggests the enhancer plays a fundamental, cross-cancer role in restraining tumor progression across multiple disease types.[2][4]

For prostate cancer, which is also heavily influenced by androgen receptor activity, this discovery could open new avenues for understanding treatment resistance. The shared genetic machinery highlights the interconnected nature of hormone-driven cancers and their underlying vulnerabilities.[4]

The collaboration with the University of Bordeaux brought additional genomic expertise to the project, uniting researchers across a 10,000-mile distance. Cross-border partnerships have become increasingly vital in modern oncology, allowing researchers to validate findings across diverse experimental models.[2][4]

The immediate clinical relevance, however, remains focused on advanced ER+ breast cancer. With several treatments designed to activate the androgen receptor currently under clinical investigation, understanding this molecular brake is highly timely for ongoing drug development.[2]

Guiding Future Therapies

The identification of HRRINT3 provides a potential biomarker for oncologists. By screening for the presence and integrity of this DNA switch, clinicians might eventually be able to predict a patient's response to androgen-activating drugs before initiating treatment.[2]

AI

"Treatments that activate the androgen receptor are already being investigated for advanced ER+ breast cancer, so understanding the molecular machinery needed for this anti-cancer effect is important," Dwyer said, emphasizing the practical applications of the discovery.[2][3]

This precision medicine approach is particularly crucial for patients whose disease has progressed despite standard interventions. When tumors stop responding to traditional estrogen-blocking hormone therapies, finding effective, targeted alternatives becomes a critical race against time for oncologists.[2]

Pointing toward the next phase of translational research, Dwyer concluded that "ultimately, this work could help us develop better ways to identify and treat patients with advanced disease who have stopped responding to hormone therapies."[2][3]

While the findings represent a significant leap in molecular oncology, the research is currently confined to experimental cell models. Translating this genetic discovery into a routine clinical diagnostic tool will require extensive validation in human trials.[2]

Moving from laboratory cell models to clinical application is a rigorous process that typically spans several years. However, because androgen-activating drugs are already in clinical trials, the timeline for integrating this biomarker into patient screening could be significantly accelerated.[2]

The next steps for the international consortium involve mapping the complete regulatory network surrounding HRRINT3. Understanding how this enhancer interacts with other genetic elements could reveal additional targets for combination therapies in treatment-resistant breast cancer.[2]